These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23780372)

  • 1. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies.
    Hanssen NM; Engelen L; Ferreira I; Scheijen JL; Huijberts MS; van Greevenbroek MM; van der Kallen CJ; Dekker JM; Nijpels G; Stehouwer CD; Schalkwijk CG
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1369-73. PubMed ID: 23780372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.
    Linssen PB; Henry RM; Schalkwijk CG; Dekker JM; Nijpels G; Brunner-La Rocca HP; Stehouwer CD
    Diab Vasc Dis Res; 2016 Jul; 13(4):278-85. PubMed ID: 27190078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD.
    Gopal P; Reynaert NL; Scheijen JL; Engelen L; Schalkwijk CG; Franssen FM; Wouters EF; Rutten EP
    Eur Respir J; 2014 Feb; 43(2):430-8. PubMed ID: 23645408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: The CODAM study.
    Scheijen JLJM; Hanssen NMJ; van Greevenbroek MM; Van der Kallen CJ; Feskens EJM; Stehouwer CDA; Schalkwijk CG
    Clin Nutr; 2018 Jun; 37(3):919-925. PubMed ID: 29381139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL).
    Hanssen NM; Beulens JW; van Dieren S; Scheijen JL; van der A DL; Spijkerman AM; van der Schouw YT; Stehouwer CD; Schalkwijk CG
    Diabetes; 2015 Jan; 64(1):257-65. PubMed ID: 24848072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
    Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
    Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.
    Fokkens BT; Mulder DJ; Schalkwijk CG; Scheijen JL; Smit AJ; Los LI
    PLoS One; 2017; 12(3):e0173379. PubMed ID: 28264049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification.
    van Eupen MG; Schram MT; Colhoun HM; Scheijen JL; Stehouwer CD; Schalkwijk CG
    Cardiovasc Diabetol; 2013 Oct; 12():149. PubMed ID: 24134530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-Bound Plasma Nε-(Carboxymethyl)lysine Is Inversely Associated With Central Obesity and Inflammation and Significantly Explain a Part of the Central Obesity-Related Increase in Inflammation: The Hoorn and CODAM Studies.
    Gaens KH; Ferreira I; van de Waarenburg MP; van Greevenbroek MM; van der Kallen CJ; Dekker JM; Nijpels G; Rensen SS; Stehouwer CD; Schalkwijk CG
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2707-13. PubMed ID: 26449750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
    O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
    J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of serum and dietary advanced glycation endproducts in relation to cardiac function and structure: The Hoorn Study.
    Kremers SHM; Remmelzwaal S; Schalkwijk CG; Elders PJM; Stehouwer CDA; van Ballegooijen AJ; Beulens JWJ
    Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3167-3175. PubMed ID: 34518083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction.
    Lieuw-A-Fa ML; van Hinsbergh VW; Teerlink T; Barto R; Twisk J; Stehouwer CD; Schalkwijk CG
    Nephrol Dial Transplant; 2004 Mar; 19(3):631-6. PubMed ID: 14767019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes.
    Peeters SA; Engelen L; Buijs J; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
    J Diabetes Complications; 2018 Mar; 32(3):325-329. PubMed ID: 29395841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry.
    Teerlink T; Barto R; Ten Brink HJ; Schalkwijk CG
    Clin Chem; 2004 Jul; 50(7):1222-8. PubMed ID: 15131022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study.
    van Dooren FE; Pouwer F; Schalkwijk CG; Sep SJ; Stehouwer CD; Henry RM; Dagnelie PC; Schaper NC; van der Kallen CJ; Koster A; Denollet J; Verhey FR; Schram MT
    Depress Anxiety; 2017 Jan; 34(1):59-67. PubMed ID: 27271340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study.
    Schram MT; Schalkwijk CG; Bootsma AH; Fuller JH; Chaturvedi N; Stehouwer CD;
    Hypertension; 2005 Jul; 46(1):232-7. PubMed ID: 15851628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dietary glycemic load is associated with higher concentrations of urinary advanced glycation endproducts: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study.
    Maasen K; van Greevenbroek MMJ; Scheijen JLJM; van der Kallen CJH; Stehouwer CDA; Schalkwijk CG
    Am J Clin Nutr; 2019 Aug; 110(2):358-366. PubMed ID: 31240298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.
    le Poole CY; van Ittersum FJ; Valentijn RM; Teerlink T; Lindholm B; Ter Wee PM; Schalkwijk CG
    Perit Dial Int; 2012; 32(1):45-54. PubMed ID: 21632443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.